Latest news with #GlaxoSmithKline
Medscape
27-05-2025
- Health
- Medscape
Newly Approved Mepolizumab Mitigates COPD Exacerbations
Adding mepolizumab to inhaled triple therapy significantly improved exacerbation outcomes compared with placebo in adults with chronic obstructive pulmonary disease (COPD), based on data from the MATINEE study presented at the American Thoracic Society (ATS) 2025 International Conference. Based on these findings, mepolizumab is newly approved by the US Food and Drug Administration for the treatment of COPD according to manufacturer GlaxoSmithKline. 'This decision is good news for patients because it allows more options for care, and it is good news for the future of COPD treatment in that there are now more options showing targets previously not identified that can improve patient outcomes,' said co-author Gerard J. Criner, MD, of the Lewis Katz School of Medicine at Temple University, Philadelphia, in a statement following the approval. Patients with COPD and type 2 inflammation are at an increased risk for frequent and severe exacerbations that may require hospitalization or emergency department visits, Alberto Papi, MD, of the University of Ferrara, Ferrara, Italy, and colleagues wrote in their abstract. Mepolizumab, a humanized monoclonal antibody that targets interleukin-5 (IL-5), significantly reduced COPD exacerbations in patients with COPD regardless of the history or severity of exacerbations in a phase 3 study known as MATINEE, the researchers wrote. In the study, the researchers randomized 804 adults aged 40 years or older with COPD to a subcutaneous dose of 100 mg of mepolizumab every 4 weeks for 52-104 weeks, or a placebo, in addition to the inhaled triple therapy of a fluticasone propionate dose of at least 500 μg/d or the equivalent, plus dual long-acting bronchodilators. Approximately 21% of the patients had a history of severe exacerbations in the past years. The mean age of the participants was approximately 66 years, and at least two thirds were men. Overall, patients treated with mepolizumab had a 21% reduced annualized rate of moderate to severe exacerbations compared with patients treated with placebo, with rate ratios of 0.75 and 0.79 for subgroups with and without a history of severe exacerbations, respectively. In addition, patients with a history of severe exacerbations had a 32% reduced rate of exacerbations requiring an emergency department visit or hospital stay. The results were durable as well, the researchers noted. The significant difference in exacerbation rates between patients treated with mepolizumab and those treated with placebo was observed at 1 year and continued for up to 104 weeks of treatment. The incidence of adverse events and serious adverse events was similar in the mepolizumab and placebo groups, the most common of which was exacerbation of COPD (11% and 15% for serious adverse events in the mepolizumab and placebo groups, respectively). Takeaways and Next Steps The researchers were surprised that mepolizumab's significant clinical impact on exacerbation reduction extended to such a broad group of patients with COPD, including those who did or did not have chronic bronchitis, and those with evidence of emphysema, Criner said in an interview. 'That mepolizumab could decrease emergency room visits and hospitalization is a significant benefit for patients,' he added. Mepolizumab made all its primary and key secondary end points with a robust safety profile, said Criner. 'Patients with COPD who have type 2 inflammation can benefit from biologic therapy, regardless of the severity of underlying airflow obstruction with or without the absence of chronic bronchitis or emphysema to reduce moderate and severe exacerbations,' he said. Additional research should target different pathways and patients who have inflammation with COPD, such as types 1 and 3, Criner noted. Approval Sparks Enthusiasm 'I'm excited to have another option to treat COPD patients who have elevated eosinophils and frequent exacerbations,' said study co-author Meilan Han, MD, of the University of Michigan, Ann Arbor, Michigan, in an interview. 'I'd like additional research to help us understand which patients experience the best response in terms of lung function and symptoms,' she added. The approval will change care of patients with COPD who are already maximized on inhaler therapies and continue to have exacerbations, 'as this is the only biologic approved for patients with blood eosinophils <= 300 cells/µL,' said Arianne K. Baldomero, MD, a pulmonologist and assistant professor of medicine at the University of Minnesota, Minneapolis, in an interview. 'The cost could be prohibitive (annual cost is almost $50,000 per year); so patients should explore insurance coverage, manufacturer assistance programs, nonprofit financial support, and discount cards to reduce their out-of-pocket expenses for mepolizumab,' she said. 'The MATINEE study was important because, despite optimal triple inhaler therapy, many high-risk patients continue to experience frequent COPD exacerbations. This trial evaluated whether adding a new therapy can further reduce exacerbations in this high-risk COPD population,' said Baldomero. However, as with other biologics, when or whether mepolizumab can be safely discontinued, and whether the risk for COPD exacerbations will return upon stopping remains unclear, said Baldomero. 'Additionally, there is limited evidence to guide whether inhaler therapies can be withdrawn while on biologics, and more research is needed to determine optimal treatment duration,' she said. Expanded MATINEE Findings Offer More Insights Several other studies of MATINEE findings were presented at the meeting. In one study, data showed that mepolizumab reduced exacerbations in patients with cardiovascular comorbidities compared with placebo. Post hoc analyses of data from the MATINEE study also were presented at the meeting to examine the effectiveness of mepolizumab in various subgroups. In one post hoc analysis, patients treated with mepolizumab had lower mean healthcare resource use per exacerbation in terms of emergency department visits, urgent care/outpatient clinic visits, and days in intensive care than patients treated with placebo. Another analysis of MATINEE study data showed that, compared with placebo, mepolizumab significantly improved exacerbation rates in patients with severely restricted airflow based on the GOLD criteria. An additional post hoc analysis showed that, compared with placebo, mepolizumab's association with improved exacerbation rates was consistent regardless of duration of COPD. Mepolizumab has been developed for the treatment of a range of IL-5 mediated diseases associated with type 2 inflammation and is also approved for use in the United States and Europe for severe asthma, eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome, and chronic rhinosinusitis with nasal polyps, according to manufacturer GlaxoSmithKline. The MATINEE study was funded by GlaxoSmithKline. Criner disclosed receiving consulting fees and research funds from GlaxoSmithKline. Han disclosed serving as a consultant for GlaxoSmithKline and multiple relationships with pharmaceutical companies outside of the MATINEE study.
Yahoo
26-05-2025
- Health
- Yahoo
Rising Demand for Preventive Healthcare Spurs Growth in Qatar's Supplement Sector - A $70.48 Million Market by 2030
The Qatar Dietary Supplements Market is set to grow from USD 48.19 Million in 2024 to USD 70.48 Million by 2030, driven by rising health consciousness, affluence, and a focus on preventive healthcare. Key players include Pfizer, Abbott, and GlaxoSmithKline. Challenges include regulatory barriers, while trends emphasize personalized nutrition. Qatari Dietary Supplements Market Dublin, May 26, 2025 (GLOBE NEWSWIRE) -- The "Qatar Dietary Supplements Market by Region, Competition, Forecast & Opportunities, 2020-2030F" has been added to offering. The dietary supplements market in Qatar is on a robust growth trajectory, valued at USD 48.19 million in 2024 and anticipated to reach USD 70.48 million by 2030, with a CAGR of 6.5%. This expansion is propelled by rising health consciousness, a shift towards preventive healthcare, and increasing affluence. As a burgeoning sector in the Middle East, Qatar's market is witnessing heightened momentum due to a growing awareness of nutrition's role in managing chronic diseases, wellness, and overall health enhancement. Factors such as the rising prevalence of obesity and diabetes are escalating the demand for supplements targeting weight management, metabolic health, and immune support. Concurrently, consumer preferences are shifting towards natural, personalized, and functional products. These trends, along with government-supported health initiatives and a burgeoning retail framework, present opportunities for both established and emerging players to cater to Qatar's evolving nutritional demands. Key Market Drivers Increasing Health Consciousness:The surge in health consciousness within Qatar's population is significantly driving the dietary supplements market. Consumers are increasingly focusing on wellness and disease prevention, fueling interest in supplements that enhance immunity, energy, weight management, and general health. The country's growing burden of chronic diseases, such as obesity and diabetes, underscores this trend. National efforts that integrate traditional wellness practices with modern health systems further bolster awareness and accessibility, making supplements a staple in daily wellness routines. Key Market Challenges Strict Regulatory Environment and Compliance Barriers: The dietary supplements sector in Qatar faces challenges from a stringent regulatory environment enforced by the Ministry of Public Health. Compliance involves comprehensive safety and quality standards, including detailed product registration and accurate labeling. These regulatory demands can delay product launches and restrict marketing agility, posing hurdles particularly for small and medium-sized enterprises lacking the infrastructure to navigate compliance requirements. Key Market Trends Personalized Nutrition and Supplementation: Personalized nutrition solutions are a growing trend in Qatar's dietary supplements market. Consumers are increasingly moving away from generic products in favor of customized regimens tailored to individual health profiles. This trend is particularly strong among affluent, health-conscious consumers in urban areas like Doha. Personalized solutions incorporate diagnostic tools such as DNA tests and lifestyle assessments to create targeted plans, supported by tech integration that enhances long-term engagement. The market's focus on digital health and preventive care aligns with the increasing demand for personalization in the wellness industry, a trend expected to gain further traction. Key Players Profiled 3A Pharma Natures & Bounty Natures Aid Fortex Nutraceuticals Geltec Co., Ltd Pfizer, Inc Holland & Barrett Abbott Laboratories, Inc. GlaxoSmithKline, Plc Olimp Labs Report Scope: By Product Type: Vitamin, Combination Dietary Supplements, Protein, Herbal Supplements, Fish Oil & Omega Fatty Acid, Others. By Form: Capsules, Tablets, Powder, Soft Gels, Liquid. By Distribution Channel: Pharmacies and Drug Stores, Online, Supermarkets and Hypermarkets, Others. By Application: Immunity, General Health, Energy & Weight Management, Bone & Joint Health, Others. By End User: Adults, Geriatric, Pregnant Females, Children, Infants. By Region: Doha, Al Rayyan, Al Wakra, Umm Slal, Rest of Qatar. Key Attributes: Report Attribute Details No. of Pages 85 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $48.19 Million Forecasted Market Value (USD) by 2030 $70.48 Million Compound Annual Growth Rate 6.5% Regions Covered Qatar For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Qatari Dietary Supplements Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Yahoo
26-05-2025
- Health
- Yahoo
Rising Demand for Preventive Healthcare Spurs Growth in Qatar's Supplement Sector - A $70.48 Million Market by 2030
The Qatar Dietary Supplements Market is set to grow from USD 48.19 Million in 2024 to USD 70.48 Million by 2030, driven by rising health consciousness, affluence, and a focus on preventive healthcare. Key players include Pfizer, Abbott, and GlaxoSmithKline. Challenges include regulatory barriers, while trends emphasize personalized nutrition. Qatari Dietary Supplements Market Dublin, May 26, 2025 (GLOBE NEWSWIRE) -- The "Qatar Dietary Supplements Market by Region, Competition, Forecast & Opportunities, 2020-2030F" has been added to offering. The dietary supplements market in Qatar is on a robust growth trajectory, valued at USD 48.19 million in 2024 and anticipated to reach USD 70.48 million by 2030, with a CAGR of 6.5%. This expansion is propelled by rising health consciousness, a shift towards preventive healthcare, and increasing affluence. As a burgeoning sector in the Middle East, Qatar's market is witnessing heightened momentum due to a growing awareness of nutrition's role in managing chronic diseases, wellness, and overall health enhancement. Factors such as the rising prevalence of obesity and diabetes are escalating the demand for supplements targeting weight management, metabolic health, and immune support. Concurrently, consumer preferences are shifting towards natural, personalized, and functional products. These trends, along with government-supported health initiatives and a burgeoning retail framework, present opportunities for both established and emerging players to cater to Qatar's evolving nutritional demands. Key Market Drivers Increasing Health Consciousness:The surge in health consciousness within Qatar's population is significantly driving the dietary supplements market. Consumers are increasingly focusing on wellness and disease prevention, fueling interest in supplements that enhance immunity, energy, weight management, and general health. The country's growing burden of chronic diseases, such as obesity and diabetes, underscores this trend. National efforts that integrate traditional wellness practices with modern health systems further bolster awareness and accessibility, making supplements a staple in daily wellness routines. Key Market Challenges Strict Regulatory Environment and Compliance Barriers: The dietary supplements sector in Qatar faces challenges from a stringent regulatory environment enforced by the Ministry of Public Health. Compliance involves comprehensive safety and quality standards, including detailed product registration and accurate labeling. These regulatory demands can delay product launches and restrict marketing agility, posing hurdles particularly for small and medium-sized enterprises lacking the infrastructure to navigate compliance requirements. Key Market Trends Personalized Nutrition and Supplementation: Personalized nutrition solutions are a growing trend in Qatar's dietary supplements market. Consumers are increasingly moving away from generic products in favor of customized regimens tailored to individual health profiles. This trend is particularly strong among affluent, health-conscious consumers in urban areas like Doha. Personalized solutions incorporate diagnostic tools such as DNA tests and lifestyle assessments to create targeted plans, supported by tech integration that enhances long-term engagement. The market's focus on digital health and preventive care aligns with the increasing demand for personalization in the wellness industry, a trend expected to gain further traction. Key Players Profiled 3A Pharma Natures & Bounty Natures Aid Fortex Nutraceuticals Geltec Co., Ltd Pfizer, Inc Holland & Barrett Abbott Laboratories, Inc. GlaxoSmithKline, Plc Olimp Labs Report Scope: By Product Type: Vitamin, Combination Dietary Supplements, Protein, Herbal Supplements, Fish Oil & Omega Fatty Acid, Others. By Form: Capsules, Tablets, Powder, Soft Gels, Liquid. By Distribution Channel: Pharmacies and Drug Stores, Online, Supermarkets and Hypermarkets, Others. By Application: Immunity, General Health, Energy & Weight Management, Bone & Joint Health, Others. By End User: Adults, Geriatric, Pregnant Females, Children, Infants. By Region: Doha, Al Rayyan, Al Wakra, Umm Slal, Rest of Qatar. Key Attributes: Report Attribute Details No. of Pages 85 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $48.19 Million Forecasted Market Value (USD) by 2030 $70.48 Million Compound Annual Growth Rate 6.5% Regions Covered Qatar For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Qatari Dietary Supplements Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Yahoo
16-05-2025
- Health
- Yahoo
Saudi Arabia Influenza Vaccine Market Trends, Competition, Forecast and Opportunities, 2020-2024 & 2025-2030 Featuring GSK, Abbott, AstraZeneca, Merck, and Johnson & Johnson
Saudi Arabia's influenza vaccine market, valued at USD 44.26 million in 2024, is projected to grow to USD 53.81 million by 2030, at a CAGR of 3.51%. Key drivers include government health campaigns and increasing public demand. Challenges include vaccine hesitancy and cold chain logistics. Major players are GlaxoSmithKline, AstraZeneca, and Merck. Saudi Arabian Influenza Vaccine Market Dublin, May 16, 2025 (GLOBE NEWSWIRE) -- The "Saudi Arabia Influenza Vaccine Market, By Region, Competition, Forecast and Opportunities, 2020-2030F" has been added to offering. The Saudi Arabia Influenza Vaccine Market, valued at USD 44.26 million in 2024, is projected to reach USD 53.81 million by 2030, growing at a CAGR of 3.51%. The nation relies primarily on a trivalent influenza vaccine (TIV), containing inactivated antigens from two subtypes of influenza virus type A and one subtype of type B, to drive its immunization efforts. The Saudi government, particularly through the Ministry of Health (MOH), plays an instrumental role in promoting influenza vaccination initiatives, focusing on high-risk groups such as the elderly, pregnant women, and those with chronic diseases. Efforts through free vaccines at healthcare facilities and mobile units have been pivotal in reducing the seasonal flu burden. Public health awareness has surged since the COVID-19 pandemic, with more individuals prioritizing preventive healthcare, including influenza vaccinations. Nevertheless, vaccine hesitancy caused by misinformation about vaccine safety and efficacy continues to challenge widespread immunization. Key Market Drivers Saudi Arabia's response to the growing prevalence of influenza includes prioritizing vaccination to curb the virus's spread. The nation ranks 82nd worldwide for seasonal influenza mortality, with 30.9 deaths per 100,000 individuals. Studies on Hajj pilgrims show influenza prevalence, prompting healthcare initiatives focusing on immunization. Efforts are further supported by institutions like the King Khaled Eye Specialist Hospital in Riyadh, which provides free vaccines to staff and dependents, ensuring records are electronically maintained for better management. Increasing vaccine access and awareness are propelling the vaccine demand, especially with heightened healthcare consciousness post-pandemic. Surge in Technological Advancements Technological advancements have enhanced vaccine development and production, boosting the influenza vaccine market. Innovations like cell-based and recombinant DNA technologies have improved vaccine effectiveness and production speed. New adjuvants also improve efficacy, particularly for older adults and immunocompromised individuals. Key Market Challenges Maintaining the optimal storage temperature for influenza vaccines remains critical. The hot climate of Saudi Arabia increases cold chain logistics challenges. Disruptions can degrade vaccine effectiveness, necessitating efficient refrigeration methods, particularly in rural areas. Additionally, the limited shelf life of vaccines demands careful inventory management. Key Market Trends The rise in demand for pediatric vaccines aligns with the MOH's initiatives to protect children from influenza, bolstered by services like Careem's home vaccination program. Such efforts reflect the Kingdom's broader public health goals, further impacting influenza vaccine demand and growth. Segmental Insights Inactivated influenza vaccines lead market growth due to their broad suitability and safety for diverse populations. Hospitals have become key vaccination centers, offering convenient access to immunizations and playing a significant role in the market's expansion. Regional Insights Northern & Central Saudi Arabia, including Riyadh, dominate the market, facilitated by healthcare services linked to religious pilgrimages and strong private sector engagement. Key Market Players GlaxoSmithKline plc. Abbott S.A. AstraZeneca PLC Merck Limited Johnson and Johnson Medical Saudi Arabia Limited Key Attributes: Report Attribute Details No. of Pages 85 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $44.26 Million Forecasted Market Value (USD) by 2030 $53.81 Million Compound Annual Growth Rate 3.5% Regions Covered Saudi Arabia Key Topics Covered: 1. Product Overview1.1. Market Definition1.2. Scope of the Market 2. Research Methodology2.1. Objective of the Study2.2. Baseline Methodology 3. Executive Summary3.1. Overview of the Market 4. Saudi Arabia Influenza Vaccine Market Outlook4.1. Market Size & Forecast4.2. Market Share & Forecast 5. Eastern Influenza Vaccine Market Outlook5.1. Market Size & Forecast5.2. Market Share & Forecast 6. Western Influenza Vaccine Market Outlook6.1. Market Size & Forecast6.2. Market Share & Forecast 7. Northern & Central Influenza Vaccine Market Outlook7.1. Market Size & Forecast7.2. Market Share & Forecast 8. Southern Influenza Vaccine Market Outlook8.1. Market Size & Forecast8.2. Market Share & Forecast 9. Market Dynamics9.1. Drivers9.2. Challenges 10. Market Trends & Developments10.1. Recent Developments 11. Policy & Regulatory Landscape 12. Saudi Arabia Economic Profile 13. Competitive Landscape For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Saudi Arabian Influenza Vaccine Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Yahoo
16-05-2025
- Health
- Yahoo
Saudi Arabia Influenza Vaccine Market Trends, Competition, Forecast and Opportunities, 2020-2024 & 2025-2030 Featuring GSK, Abbott, AstraZeneca, Merck, and Johnson & Johnson
Saudi Arabia's influenza vaccine market, valued at USD 44.26 million in 2024, is projected to grow to USD 53.81 million by 2030, at a CAGR of 3.51%. Key drivers include government health campaigns and increasing public demand. Challenges include vaccine hesitancy and cold chain logistics. Major players are GlaxoSmithKline, AstraZeneca, and Merck. Saudi Arabian Influenza Vaccine Market Dublin, May 16, 2025 (GLOBE NEWSWIRE) -- The "Saudi Arabia Influenza Vaccine Market, By Region, Competition, Forecast and Opportunities, 2020-2030F" has been added to offering. The Saudi Arabia Influenza Vaccine Market, valued at USD 44.26 million in 2024, is projected to reach USD 53.81 million by 2030, growing at a CAGR of 3.51%. The nation relies primarily on a trivalent influenza vaccine (TIV), containing inactivated antigens from two subtypes of influenza virus type A and one subtype of type B, to drive its immunization efforts. The Saudi government, particularly through the Ministry of Health (MOH), plays an instrumental role in promoting influenza vaccination initiatives, focusing on high-risk groups such as the elderly, pregnant women, and those with chronic diseases. Efforts through free vaccines at healthcare facilities and mobile units have been pivotal in reducing the seasonal flu burden. Public health awareness has surged since the COVID-19 pandemic, with more individuals prioritizing preventive healthcare, including influenza vaccinations. Nevertheless, vaccine hesitancy caused by misinformation about vaccine safety and efficacy continues to challenge widespread immunization. Key Market Drivers Saudi Arabia's response to the growing prevalence of influenza includes prioritizing vaccination to curb the virus's spread. The nation ranks 82nd worldwide for seasonal influenza mortality, with 30.9 deaths per 100,000 individuals. Studies on Hajj pilgrims show influenza prevalence, prompting healthcare initiatives focusing on immunization. Efforts are further supported by institutions like the King Khaled Eye Specialist Hospital in Riyadh, which provides free vaccines to staff and dependents, ensuring records are electronically maintained for better management. Increasing vaccine access and awareness are propelling the vaccine demand, especially with heightened healthcare consciousness post-pandemic. Surge in Technological Advancements Technological advancements have enhanced vaccine development and production, boosting the influenza vaccine market. Innovations like cell-based and recombinant DNA technologies have improved vaccine effectiveness and production speed. New adjuvants also improve efficacy, particularly for older adults and immunocompromised individuals. Key Market Challenges Maintaining the optimal storage temperature for influenza vaccines remains critical. The hot climate of Saudi Arabia increases cold chain logistics challenges. Disruptions can degrade vaccine effectiveness, necessitating efficient refrigeration methods, particularly in rural areas. Additionally, the limited shelf life of vaccines demands careful inventory management. Key Market Trends The rise in demand for pediatric vaccines aligns with the MOH's initiatives to protect children from influenza, bolstered by services like Careem's home vaccination program. Such efforts reflect the Kingdom's broader public health goals, further impacting influenza vaccine demand and growth. Segmental Insights Inactivated influenza vaccines lead market growth due to their broad suitability and safety for diverse populations. Hospitals have become key vaccination centers, offering convenient access to immunizations and playing a significant role in the market's expansion. Regional Insights Northern & Central Saudi Arabia, including Riyadh, dominate the market, facilitated by healthcare services linked to religious pilgrimages and strong private sector engagement. Key Market Players GlaxoSmithKline plc. Abbott S.A. AstraZeneca PLC Merck Limited Johnson and Johnson Medical Saudi Arabia Limited Key Attributes: Report Attribute Details No. of Pages 85 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $44.26 Million Forecasted Market Value (USD) by 2030 $53.81 Million Compound Annual Growth Rate 3.5% Regions Covered Saudi Arabia Key Topics Covered: 1. Product Overview1.1. Market Definition1.2. Scope of the Market 2. Research Methodology2.1. Objective of the Study2.2. Baseline Methodology 3. Executive Summary3.1. Overview of the Market 4. Saudi Arabia Influenza Vaccine Market Outlook4.1. Market Size & Forecast4.2. Market Share & Forecast 5. Eastern Influenza Vaccine Market Outlook5.1. Market Size & Forecast5.2. Market Share & Forecast 6. Western Influenza Vaccine Market Outlook6.1. Market Size & Forecast6.2. Market Share & Forecast 7. Northern & Central Influenza Vaccine Market Outlook7.1. Market Size & Forecast7.2. Market Share & Forecast 8. Southern Influenza Vaccine Market Outlook8.1. Market Size & Forecast8.2. Market Share & Forecast 9. Market Dynamics9.1. Drivers9.2. Challenges 10. Market Trends & Developments10.1. Recent Developments 11. Policy & Regulatory Landscape 12. Saudi Arabia Economic Profile 13. Competitive Landscape For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Saudi Arabian Influenza Vaccine Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
